Clinical Trials: EVP-6124 Phase 2b Clinical Trial in Schizophrenia
Positive Study Results for Schizophrenia Drug
Drug Discovery & Development
December 05, 2011
"EnVivo Pharmaceuticals announced the analysis of a completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia."
Read the full report